%0 Journal Article
%T Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
%A Constance Delaugerre
%A H¨¦lo£¿se M. Delagr¨¨verie
%A Jonathan Z. Li
%A Sharon R. Lewin
%A Steven G. Deeks
%J Archive of "Open Forum Infectious Diseases".
%D 2016
%R 10.1093/ofid/ofw189
%X In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results
%K anti-HIV agents
%K clinical trial
%K HIV-1
%K latency-reversing agents
%K viral reservoir
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066458/